Idorsia Ltd
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IDIA.SW | HRMY | CRVS | ZVRA | IVA | IDYA | |
|---|---|---|---|---|---|---|
| Market cap | 1.16B | 2.00B | 889.16M | 663.32M | 914.17M | 3.13B |
| P/E (TTM) | — | 11.4 | — | 9.2 | — | — |
| Forward P/E | 78.1 | 4.9 | -9.9 | 10.4 | -5.2 | -7.9 |
| Price/book | -0.9 | 1.9 | 3.9 | 4.1 | 13.8 | 2.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +31.67% | +11.23% | +35.17% | +1.89% | −7.42% | +8.41% |
| Today | −2.09% | −7.04% | +7.53% | +8.87% | −3.97% | +3.29% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IDIA.SW news ›Idorsia Ltd (IDRSF) Shareholder/Analyst Call - Slideshow
2026-11-04. The following slide deck was published by Idorsia Ltd in conjunction with this event. The following slide deck was published by Idorsia Ltd in conjunction with this event.
FDA Breakthrough status for Idorsia’s daridorexant - The Pharma Letter
FDA Breakthrough status for Idorsia’s daridorexant The Pharma Letter
Therapy Designation Granted By The FDA For Daridorexant In Pediatric Insomnia Disorder
TradingView Therapy Designation Granted By The FDA For Daridorexant In Pediatric Insomnia Disorder
New mouse tool targets microvascular endothelial cells in muscle and fat
Scientists have created a CTRP9-CreERT2 knock-in mouse line whose tamoxifen-inducible reporter selectively labels microvascular endothelial cells in heart, skeletal muscle, tongue and adipose tissue. Researchers have built a genetically…
Idorsia seeks US label update for QUVIVIQ daytime functioning benefits – first patients enrolled in Dari-Dream
Building on established clinical evidence, Dari-Dream is designed to further characterize the impact of QUVIVIQ on daytime functioning and support its inclusion in the US prescribing information. Allschwil, Switzerland – October 27,…
A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder
In a Phase 2 study in pediatric insomnia disorder, in addition to marked improvements in sleep measures, daridorexant 50 mg showed an unexpected pattern of improvement in affect and behavior, cognition, and daily activities in participants…
Idorsia presents outstanding results with daridorexant in children and adolescents with insomnia and an expanding body of evidence in adults at Sleep Europe 2026
Daridorexant, a dual orexin receptor antagonist, is the first investigational treatment in its class to demonstrate positive results in pediatric insomnia disorder, an area in which significant unmet needs remain for children and their…
Idorsia | Presentation of the Phase 2 results of daridorexant in pediatric insomnia
+41 58 844 00 00 Please get in touch with us via the contact form by clicking "Next". Learn more about our Governance by clicking "Next" Idorsia attempts to ensure that your Personal Data are updated, accurate, and complete according to…
Idorsia Ltd Announces New Results Across Pediatric, Adult and Real-World Insomnia Settings Highlight the Expanding Clinical Evidence for Daridorexant At Sleep Europe 2026
Idorsia Ltd. continued its commitment to advancing the science of sleep and insomnia at Sleep Europe 2026, taking place in Maastricht, the Netherlands, from October 20 to 23, 2026. The scientific...
After tax other income/expense of Idorsia Ltd. – XETR:19T
TradingView After tax other income/expense of Idorsia Ltd.
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com17
- idorsia.com1
- seekingalpha.com1
- tradingview.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 20 articles, not a forecast.